Associate Chair/Senior Lecturer
The main line of my methodologic statistical research involves the design and analysis of studies involving mixtures of discrete and continuous outcomes, with a focus on dose-response modeling and quantitative risk assessment. Toxicologic and other early evaluation studies in animals are a specific application area, but problems related to multiple outcomes arise in a variety of research contexts.
One important application of such methods is the determination of overall risk from an exposure to an agent (drug, chemical, etc.) when the outcomes are naturally multivariate in nature. Although assessing probabilistic risk is usually straightforward, with a single outcome, in the multivariate setting the situation is often more complex because outcomes may be observed simultaneously or in a hierarchical fashion. The statistical analysis must carefully account for these features of the response profile.
My collaborative research in cancer involves statistical support on the design, monitoring and analysis of clinical trials in gastrointestinal malignancies, quality of life and laboratory/translational science study design and analysis in gatrointestinal malignancies and quality of care/outcomes research in lung cancer and colorectal cancer.
Dr. Catalano received his ScD in biostatistics from Harvard School of Public Health (HSPH) in 1991. He then completed a two year postdoctoral fellowship at HSPH and DFCI, joined the faculty in 1993, and became associate chair of the Department in 2001 and senior lecturer in 2005. His collaborative work is primarily in cancer clinical trials with the Eastern Cooperative Oncology Group, in outcomes and quality of care research in the CanCORS Consortium and in investigating the health effects of air pollution. His methodological research is in multiple outcomes modeling and quantitative risk assessment.
Mitin T, Chen Y-H, Catalano PJ, Floyd SR, Kasper EM, Mahadevan A. The role of systemic disease status in treatment outcomes for patients with newly diagnosed brain oligometastases and treated with stereotactic radiosurgery alone. J Radiat Oncol 2013; Aug 25 [epub ahead of print].
Gilmore D, Schulz M, Liu R, Zubris KA, Padera RF, Catalano PJ, Grinstaff MW, Colson YL. Cytoreductive Surgery and Intraoperative Administration of Paclitaxel-loaded Expansile Nanoparticles Delay Tumor Recurrence in Ovarian Carcinoma. Ann Surg Oncol. 2013 May;20(5):1684-93.
Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M,
Overmoyer BA, Harris JR, Brock JE. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013 Mar;20(3):811-8.
Liu R, Gilmore DM, Zubris KA, Xu X, Catalano PJ, Padera RF, Grinstaff MW,
Colson YL. Prevention of nodal metastases in breast cancer following the
lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials. 2013 Feb;34(7):1810-9.
Catalano PJ, Ayanian JZ, Weeks JC, Kahn KL, Landrum MB, Zaslavsky AM, Lee J, Pendergast J, Harrington DP; Cancer Care Outcomes Research Surveillance Consortium. Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care. 2013 Feb;51(2):e9-15.
Najita JS, Catalano PJ. On Determining the BMD from Multiple Outcomes in
Developmental Toxicity Studies when One Outcome is Intentionally Missing. Risk Anal. 2012 Dec 12.
Leung CW, Ding EL, Catalano PJ, Villamor E, Rimm EB, Willett WC. Dietary
intake and dietary quality of low-income adults in the Supplemental Nutrition Assistance Program. Am J Clin Nutr. 2012 Nov;96(5):977-88.
Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012 Oct 25;367(17):1616-25.
Bruno Garza JL, Catalano PJ, Katz JN, Huysmans MA, Dennerlein JT. Developing a framework for predicting upper extremity muscle activities, postures, velocities, and accelerations during computer use: the effect of keyboard use, mouse use, and individual factors on physical exposures. J Occup Environ Hyg. 2012;9(12):691-8.
Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54.
Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium - The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium is an NCI-funded study that is a network of sites around the country that are conducting a population-based study of access to and outcomes from cancer care, with special focus on ethnic subgroups and subgroups defined by age.
Eastern Cooperative Oncology Group - The Eastern Cooperative Oncology Group (ECOG) is one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers.